Instances of MTC in individuals dealt with with liraglutide, A different GLP-one receptor agonist, have already been documented from the postmarketing period; the information in these studies are insufficient to determine or exclude a causal connection involving MTC and GLP-one receptor agonist use in individuals.Scientists are investigating a vari